- Home
- ECPG vs ELVN Comparison
ECPG vs ELVN Comparison
Compare ECPG & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECPG
- ELVN
- Stock Information
- Founded
- ECPG 1998
- ELVN 2016
- Country
- ECPG United States
- ELVN United States
- Employees
- ECPG N/A
- ELVN N/A
- Industry
- ECPG Finance Companies
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- ECPG Finance
- ELVN Health Care
- Exchange
- ECPG Nasdaq
- ELVN Nasdaq
- Market Cap
- ECPG 806.1M
- ELVN 927.8M
- IPO Year
- ECPG 1999
- ELVN 2020
- Fundamental
- Price
- ECPG $40.51
- ELVN $18.42
- Analyst Decision
- ECPG Strong Buy
- ELVN Strong Buy
- Analyst Count
- ECPG 3
- ELVN 4
- Target Price
- ECPG $62.67
- ELVN $39.25
- AVG Volume (30 Days)
- ECPG 354.2K
- ELVN 260.6K
- Earning Date
- ECPG 05-07-2025
- ELVN 05-13-2025
- Dividend Yield
- ECPG N/A
- ELVN N/A
- EPS Growth
- ECPG N/A
- ELVN N/A
- EPS
- ECPG N/A
- ELVN N/A
- Revenue
- ECPG $1,380,750,000.00
- ELVN N/A
- Revenue This Year
- ECPG $21.62
- ELVN N/A
- Revenue Next Year
- ECPG $10.12
- ELVN N/A
- P/E Ratio
- ECPG N/A
- ELVN N/A
- Revenue Growth
- ECPG 11.49
- ELVN N/A
- 52 Week Low
- ECPG $26.45
- ELVN $13.30
- 52 Week High
- ECPG $51.77
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- ECPG 66.74
- ELVN 47.86
- Support Level
- ECPG $32.27
- ELVN $17.76
- Resistance Level
- ECPG $36.32
- ELVN $20.79
- Average True Range (ATR)
- ECPG 1.55
- ELVN 1.37
- MACD
- ECPG 0.90
- ELVN 0.12
- Stochastic Oscillator
- ECPG 92.47
- ELVN 45.39
About ECPG Encore Capital Group Inc
Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumers repay their obligations and work toward financial recovery. Encore has only a reportable segment portfolio purchasing and recovery.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.